RIGL — Rigel Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
- $189.44m
- $192.11m
- $116.88m
- 55
- 49
- 73
- 61
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 59.3 | 109 | 149 | 120 | 117 |
Cost of Revenue | |||||
Gross Profit | 58.4 | 108 | 148 | 118 | 110 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 128 | 138 | 162 | 176 | 137 |
Operating Profit | -69.1 | -29 | -12.5 | -55.5 | -20.5 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -66.9 | -29.7 | -17.3 | -58.6 | -25.1 |
Provision for Income Taxes | |||||
Net Income After Taxes | -66.9 | -29.7 | -17.9 | -58.6 | -25.1 |
Net Income Before Extraordinary Items | |||||
Net Income | -66.9 | -29.7 | -17.9 | -58.6 | -25.1 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -66.9 | -29.7 | -17.9 | -58.6 | -25.1 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.4 | -0.176 | -0.092 | -0.332 | -0.144 |